Trial Profile
Treatment with zoledronic acid subsequent to denosumab in osteoporosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Metabolic bone diseases; Osteoporosis
- Focus Therapeutic Use
- Acronyms ZOLARMAB
- 01 Jul 2021 Results assessing long-term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab published in the Journal of Bone and Mineral Research
- 06 Aug 2020 Status changed from active, no longer recruiting to completed.
- 09 Jul 2020 Planned End Date changed from 1 Dec 2020 to 1 Sep 2020.